FDA: Recall of methylprednisolone sodium succinate for injection
Editor's Note
The Food and Drug Administration (FDA) on March 6 announced the recall by Sagent Pharmaceuticals (Schaumburg, Illinois) of 10 lots of methylprednisolone sodium succinate for injection, USP, 40 mg, 125 mg, and 1 g.
The recall was initiated because of the discovery of high out of specification impurity results detected during routine quality testing of stability samples for two lots. The impurity has not yet been identified.
The products were manufactured by Gland Pharma Ltd (Ameerpet, Hyderabad, India) and distributed by Sagent Pharmaceuticals.
Posted 03/06/2018] AUDIENCE: Pharmacy, Risk Manager ISSUE: Sagent Pharmaceuticals, Inc. announced the voluntary nationwide recall of ten lots of Methylprednisolone Sodium Succinate for Injection, USP, 40mg, 125mg, and 1g. A detailed listing of products and lots is listed in the recall notice. These products were manufactured by Gland Pharma Ltd.
Free Daily News
- Survey assesses continued impact of Change Healthcare cyberattack
- WHO sounds alarm on potential spread of bird flu
- Allison Massari to deliver hopeful, empowering keynote address at OR Manager Conference 2024
- Neurosurgery trial: Early evacuation improves long-term hemorrhage outcomes
- Drug shortages higher than ever
- FDA announces class 1 recalls for premixed embolic, infusion pump software
- Academic medical centers identify performance-improvement priorities
- Propofol anesthesia for colonoscopy could help find polyps, prevent cancer
- FDA Class 1 recall renews concern about historically problematic heart pumps
- New physician compensation report reveals modest pay gains but growing discontent with the profession